Table 5.
Clinical characteristics by tissue testing results.
| Clinical Characteristic | LS DM (N=22) N (%) |
Screen Positive 1 (N=31) N (%) |
Sporadic Cancer2 (N-328) N (%) |
p-value LS vs Screen Positive | p-value LS vs Sporadic |
|---|---|---|---|---|---|
|
| |||||
| Age at Diagnosis, mean (SD) | 52 (9.1) | 60 (10.6) | 62 (10.9) | p<0.01 | p<0.01 |
|
| |||||
| Age at Diagnosis <50 | P=0.04 | p<0.01 | |||
| Yes | 10 (46) | 6 (19) | 34 (10) | ||
| No | 12 (55) | 25 (81) | 294 (90) | ||
|
| |||||
| BMI | p=0.17 | p<0.01 | |||
| Not Overweight | 8 (36) | 6 (19) | 47 (14) | ||
| Overweight | 14 (64) | 25 (81) | 281 (86) | ||
|
| |||||
| Tumor Location | P=0.13 | p<0.01 | |||
| Corpus | 14 (70) | 27 (87) | 295 (93) | ||
| Lower Uterine Segment | 6 (30) | 4 (13) | 22 (7) | ||
|
| |||||
| SGO 5–10% Criteria | P=0.05 | p<0.01 | |||
| Yes | 13 (59) | 10 (32) | 78 (24) | ||
| No | 9 (71) | 21 (68) | 250 (76) | ||
|
| |||||
| FDR3 or SDR4 with LS associated CA | p=0.22 | p<0.01 | |||
| Yes | 13 (59) | 13 (42) | 108 (33) | ||
| No | 9 (41) | 18 (58) | 220 (67) | ||
1
Screen Positive = loss of MLH1 expression (without MLH1 methylation), loss of MSH2, MSH6, or PMS2 by IHC, or MSI-high tumor lacking MLH1 methylation with no identified DM in a LS gene,
2
Sporadic Cancer = intact tumor testing with no identified DM in a LS gene,
3
FDR = first degree relative,
4
SDR = second degree relative